Chase Investment Counsel Corp Invests $758,000 in Harmony Biosciences Holdings, Inc. $HRMY

Chase Investment Counsel Corp acquired a new position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) in the fourth quarter, Holdings Channel.com reports. The fund acquired 20,266 shares of the company’s stock, valued at approximately $758,000.

A number of other institutional investors have also recently made changes to their positions in the business. Robeco Institutional Asset Management B.V. boosted its position in shares of Harmony Biosciences by 0.6% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 47,085 shares of the company’s stock worth $1,762,000 after purchasing an additional 298 shares in the last quarter. Thrivent Financial for Lutherans boosted its position in shares of Harmony Biosciences by 1.2% in the 3rd quarter. Thrivent Financial for Lutherans now owns 28,639 shares of the company’s stock worth $789,000 after purchasing an additional 348 shares in the last quarter. Nebula Research & Development LLC lifted its position in Harmony Biosciences by 2.0% during the 2nd quarter. Nebula Research & Development LLC now owns 17,403 shares of the company’s stock worth $550,000 after acquiring an additional 348 shares during the period. Amalgamated Bank lifted its position in Harmony Biosciences by 3.8% during the 3rd quarter. Amalgamated Bank now owns 11,328 shares of the company’s stock worth $312,000 after acquiring an additional 417 shares during the period. Finally, Profund Advisors LLC lifted its position in Harmony Biosciences by 5.1% during the 3rd quarter. Profund Advisors LLC now owns 10,803 shares of the company’s stock worth $298,000 after acquiring an additional 520 shares during the period. Institutional investors and hedge funds own 86.23% of the company’s stock.

Harmony Biosciences Stock Performance

NASDAQ HRMY opened at $30.09 on Monday. The stock has a market capitalization of $1.74 billion, a price-to-earnings ratio of 12.13, a PEG ratio of 0.20 and a beta of 0.97. Harmony Biosciences Holdings, Inc. has a twelve month low of $25.52 and a twelve month high of $40.87. The company has a current ratio of 3.58, a quick ratio of 3.56 and a debt-to-equity ratio of 0.15. The stock has a 50-day moving average of $29.24 and a 200 day moving average of $33.14.

Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.55 earnings per share for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.21). The company had revenue of $215.39 million for the quarter, compared to analyst estimates of $220.84 million. Harmony Biosciences had a return on equity of 17.19% and a net margin of 16.20%.The business’s revenue was up 16.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.78 earnings per share. Sell-side analysts anticipate that Harmony Biosciences Holdings, Inc. will post 3.34 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have commented on HRMY shares. Weiss Ratings cut Harmony Biosciences from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, April 29th. Wall Street Zen cut Harmony Biosciences from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Mizuho set a $50.00 price target on Harmony Biosciences in a research report on Thursday, February 19th. Truist Financial lifted their price target on Harmony Biosciences from $25.00 to $29.00 and gave the stock a “hold” rating in a research report on Friday, May 8th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $55.00 price target on shares of Harmony Biosciences in a research report on Wednesday, February 25th. Four research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Harmony Biosciences presently has a consensus rating of “Hold” and an average target price of $40.89.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc is a commercial?stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.